Company:Keystone Nano
From HandWiki
Keystone Nano, founded in 2005, is an American-based company based in Pennsylvania, that creates nanoscale products to diagnose and treat human disease and improve the quality of life.[1]
Patents
Keystone Nano Inc. and team has been granted the follow patents:
- US Patent (8,747,891) - Awarded to The Penn State Research Foundation and Keystone Nano's Chief Medical Officer Mark Kester, this patent describes the process of loading Ceramide nano-scale liposomes with anti-cancer compounds and create a combination of therapies that benefit from the therapeutic activity of both Ceramide and the anti-cancer compound. This process improves the delivery of both compounds by targeting tumors and extending the time of biological activity.[2][3]
FDA Approval
In January 2017, the FDA approved the investigational new drug application, NanoLiposome, to assess the product as a form of treatment for solid tumors. Phase 1 trials will take place at the University of Maryland, University of Virginia, and the Medical University of South Carolina.[4]
Compound
Keystone was approved in 2017 to begin clinical trials to assess ceramide nanoliposome for possible use in treating cancer.[5]
References
- ↑ "Company Overview of Keystone Nano, Inc.". https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=59073403. Retrieved 10 August 2015.
- ↑ "Patent for the Novel Cancer Therapies – Ceramide Nanoliposomes". http://www.nanotech-now.com/news.cgi?story_id=51035. Retrieved 9 August 2015.
- ↑ Falce, Lori. "Local firm builds on Penn State patent to fight cancer". Archived from the original on 23 September 2015. https://web.archive.org/web/20150923202031/http://www.centredaily.com/2015/03/12/4648362_local-firm-builds-on-penn-state.html?rh=1. Retrieved 10 August 2015.
- ↑ "FDA Approves Investigational New Drug Application for Ceramide NanoLiposome". http://www.pharmacytimes.com/product-news/fda-approves-investigational-new-drug-application-for-ceramide-nanoliposome. Retrieved 14 January 2017.
- ↑ "Investigational cancer compound receives FDA approval to begin human trials". http://news.psu.edu/story/473555/2017/06/29/research/investigational-cancer-compound-receives-fda-approval-begin-human.
External links
 |  |
